Clinical Trials

Gates Institute supports the following trials of chimeric antigen receptor (CAR) T-cell therapy at CU Anschutz Medical Campus:

• Phase 1 study of feasibility and safety of UCD19 CAR T cells in adult patients with relapsed and/or refractory B-cell non-Hodgkin lymphoma (B-NHL); opened 2020 at UCHealth.
• Phase 1/2 dose escalation and preliminary efficacy study of UCD19 CAR T cells in pediatric patients with relapsed and/or refractory B-cell acute lymphoblastic leukemia (B-ALL) and B-NHL; opened 2021 at Children’s Hospital Colorado.
• Phase 1/1b study of bispecific CD19x22 CAR T cells in adolescent and adult patients with relapsed and/or refractory B-NHL; opened 2022 at UCHealth.
• Phase 1 Safety and Tolerability Trial of CD19 CAR T Cells in Adult Patients with B-cell Acute Lymphoblastic Leukemia (B-ALL) with Minimal Residual Disease (MRD) Positivity at First Complete Remission; enrollment opened July 2023 at UCHealth. 

For information on enrollment in clinical trials supported by Gates Institute, please contact GatesInstituteCELLS@cuanschutz.edu.